LAVAL, QC – November 5, 2025 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a globally diversified pharmaceutical company, and OraPharma, its dental products business, today announced OraPharma’s commercial expansion into Canada and Puerto Rico. This strategic move reflects OraPharma’s commitment to improving oral health awareness, providing access to periodontal disease management treatments and strengthening partnerships with local distributors and dental professionals in these markets.
Periodontal disease is still one of the most prevalent chronic oral diseases worldwide. Findings from the Global Burden of Disease (2021) study reveal that over 1 billion people are affected worldwide.1 In Canada, the Canadian Dental Association estimates that seven out of ten Canadians will develop gingivitis in their lifetime.2 In Puerto Rico, 44.5% of seniors live with moderate to severe periodontal disease.3 These data highlight the urgent need for greater awareness and improved access to treatment options.
For more than two decades, OraPharma has been dedicated to advancing periodontal care. Its flagship product, Arestin®is the only antibiotic approved by the Food and Drug Administration (FDA) for use with scaling and root planing (SRP) as part of the management of periodontal disease and is backed by over 20 years of clinical experience. Arestin is indicated as an adjunct to SRP to reduce pocket depth in adult periodontitis, assisting dental professionals in providing comprehensive care. This expansion into Canada and Puerto Rico is intended to improve access to periodontal care in these regions.
“OraPharma remains committed to addressing periodontal disease, a condition that affects more than 1 billion people worldwide,” said Tom Stern, Vice President and General Manager, OraPharma, Bausch Health. “By expanding access to Arestin in Canada and Puerto Rico, we aim to help address gaps in care and provide dental professionals with a treatment option to support improved oral health for adult patients with periodontitis.”
What is ARESTIN?
ARRESTIN® Microspheres (minocycline HCl), 1 mg is used in conjunction with scaling and root planing (SRP) procedures to treat patients with adult periodontitis (gum disease). ARRESTIN® can be used as part of a general oral health program that includes good brushing and flossing habits and SRP.
IMPORTANT SAFETY INFORMATION
- Do not use ARESTIN if: you are allergic to minocycline or tetracyclines, ask your dentist if you are not sure. Do not use ARESTIN in children, pregnant or lactating women, as the use of tetracycline class drugs, including ARESTIN, during tooth development may cause permanent tooth discoloration.
- ARESTIN may make you sensitive to sunlight. Patients exposed to direct sunlight or UV light may develop severe sunburn. At the first sign of skin redness, call your dentist.
- Serious allergic reactions have occurred with oral minocycline. Get emergency help right away if you develop any signs of an allergic reaction, such as shortness of breath, swelling of the face, throat, and tongue, rash, hives, itching, fever, or enlarged lymph nodes.
- Tetracyclines, including oral minocycline, have been associated with the development of autoimmune syndromes with symptoms such as joint pain, muscle pain, rash, swelling, fever, enlarged lymph nodes, and general body weakness.
- Tell your dentist about any medicines you take and any health problems you have, including whether you have had oral candidiasis (‘thrush’).
- ARESTIN has not been studied in patients with weakened immune systems, such as patients with HIV infections or diabetes, or in patients receiving chemotherapy or radiation.
- The most commonly reported non-dental side effects were headache, infection, flu-like symptoms, and pain.
We encourage you to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
See full prescribing information at arrestin.com/pi OR click here for complete prescribing information.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company that enriches lives through our relentless pursuit of better healthcare outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through our control of Bausch + Lomb Corporation. Our ambition is to be a global integrated healthcare company trusted and valued by patients, physicians, employees and investors. OraPharma is a specialty pharmaceutical company committed to working with dental professionals to improve oral health. More information can be found at www.orapharma.com. For more information about Bausch Health, visit www.bauschhealth.com and connect with us LinkedIn.
Forward-looking statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the US Private Securities Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words “will,” “expects,” “hopes, plans,” “expects,” “hopes, plans,” “should,” “could,” “will,” “may”, “believes”, “subject to” and variations or similar expressions. These statements are not historical facts or assurances of future performance, are based on management’s current expectations and beliefs, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties related more broadly to Bausch Health’s overall business, including those more fully described in Bausch Health’s most recent annual and quarterly reports and described from time to time in Bausch Health’s other filings with the US Securities and Exchange Commission and Canadian Securities Administrators, which factors are incorporated by reference herein. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this announcement or to reflect actual results, except as required by law.
REFERENCE:
(1) Hu M, Zhang R, Wang R, Wang Y, Guo J. Global, regional and national burden of periodontal disease from 1990 to 2021 and projections to 2040: an analysis of the Global Burden of Disease Study 2021. Front Oral Health. 2025? 6:1627746. doi:10.3389/froh.2025.1627746. [frontiersin.org]
(2) Canadian Dental Association
(3) Low vitamin D status is strongly associated with periodontitis in Puerto Rican adults BMC Oral Health
ORAPHARMA is a trademark of Bausch Health Companies Inc. or its subsidiaries.
© 2025 Bausch Health Companies Inc. or its subsidiaries.
Source: Bausch Health
